Table 5.
Literature summary a.
| Author | Histology | No of Pat. | PET metric Corr. with Survival | PET metric Not Corr. with Survival | Cut off | AUC |
|---|---|---|---|---|---|---|
| Hong 2014 [10] | STS (but including ES (8)) | 55 | SUVmax(+avg) | MTV + TLG | - | - |
| Andersen * 2015 [9] | STS (55) | 55 | SUVmax T/B TLG MTV40% |
17.7 7.2 265.6 g 25.0 mL |
0.797 0.787 0.780 0.694 |
|
| Andersen * 2015 [13] | BS (37 including 6 ES) | 37 | TLG MTV40% |
SUVmax T/B |
11.6 8.0 149.4 g 32.6 mL |
0.630 0.593 0.773 0.727 |
| Schuetze 2005 [30] | STS | 47 | SUVmax correlating with DFS und MFS but not OAS | (SUVmax (OS)) | Predefined > 6 | - |
| Skamene 2014 [31] | STS, BS and ES | 81, 23 and 16 | SUVmax | 10.3 | - | |
| Chang 2015 [11] | STS (Synovial sarcoma) | 20 | SUVmax MTV2.5abs TLG |
6.1 166.2 mL 691.7 g |
- - - |
|
| Casey 2014 [32] | STS (Rhabdomyosarcoma) | 107 | SUVmax | (predefined 6.0)/9.5 | - | |
| Choi 2013 [12] | STS | 76 | TLG SUVmax MTV40% |
250 g 6.0 40 cm3 |
0.833 0.771 0.667 |
|
| Ha 2016 [33] | STS (head and neck) | 36 | SUVmax SUVpeak MTV TLG |
Tu Vol | 7.0 5.0 20 mL 150.0 g 15.0 mL |
0.779 0.753 0.716 0.739 0.682 |
| Hwang 2016 [31] | ES | 34 | SUVmax | 5.8 | - | |
| Salem 2015 [19] | ES | 28 | SUVmax | 11.6 | - | |
| Jamet 2017 [17] | ES | 32 | SUVmax SUVpeak |
MTV TLG |
17.0 12.5 - - |
- - - - |
| Costelloe 2009 [15] | BS (Osteosarcoma) | 31 | SUVmax (only PFS not OS) TLG |
(SUVmax (OS)) | - - |
- - |
a: T/B = Tumor Background ratio, MFS = Metastatic free survival, PFS = progression free survival und OS =overall survival). * Two publications with the same population merged.